James Peyer - Feb 17, 2022 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Director, 10%+ Owner
Signature
/s/ Erin Hoffert, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Feb 17, 2022
Transactions value $
$80,187
Form type
4
Date filed
2/22/2022, 10:36 AM
Previous filing
Feb 16, 2022
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Purchase $20.6K +4.95K +0.1% $4.17 5.19M Feb 17, 2022 See Footnote F1, F2
transaction SNSE Common Stock Purchase $59.6K +15K +0.29% $3.97 5.21M Feb 18, 2022 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.